A

Apogee Therapeutics Inc
NASDAQ:APGE

Watchlist Manager
Apogee Therapeutics Inc
NASDAQ:APGE
Watchlist
Price: 79.86 USD -2.5% Market Closed
Market Cap: $5.5B

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Apogee Therapeutics Inc
NASDAQ:APGE
5.5B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Apogee Therapeutics Inc
Glance View

Market Cap
5.5B USD
Industry
Biotechnology

In the dynamic landscape of biopharmaceutical innovation, Apogee Therapeutics Inc. has carved out a niche by focusing on the development of first-in-class and best-in-class antibody therapies aimed at challenging the standard paradigms of treatment for immunological diseases. Born from the convergence of advanced biological insights and cutting-edge technology, Apogee is on a relentless pursuit to decode the intricate immune responses involved in a multitude of chronic conditions. At its core, the company leverages a proprietary platform that integrates protein engineering with a robust understanding of immune pathways, enabling the design and optimization of novel antibodies that precisely target elusive disease mechanisms. This tailor-fitted framework propels Apogee to the forefront of therapeutic innovation, where science and strategic insight intersect. Revenue generation at Apogee Therapeutics hinges on a two-pronged strategy. On one hand, it is deeply invested in progressing its in-house portfolio of therapeutic candidates through clinical trials, ultimately aiming to secure regulatory approvals and bring these therapies to market. This approach positions the company to earn substantial returns by addressing significant unmet medical needs and capturing market share within the lucrative immunotherapy segment. Concurrently, Apogee engages in strategic collaborations and licensing agreements with other biotechnology firms and pharmaceutical giants. These partnerships not only provide a steady stream of income through milestone payments and royalties but also enhance the company's intellectual property portfolio and extend its research capabilities. In essence, Apogee Therapeutics Inc. thrives by balancing innovation with strategic alliances, generating revenue while advancing the frontiers of immunological treatment.

APGE Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top